Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |1 May 2007

Adding Infliximab to the Treatment Regimen for Polymyalgia Rheumatica Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full report titled “Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica. A Randomized Trial.” It is in the 1 May 2007 issue of Annals of Internal Medicine (volume 146, pages 631-639). The authors are C. Salvarani, P.L. Macchioni, C. Manzini, G. Paolazzi, A. Trotta, P. Manganelli, M. Cimmino, R. Gerli, M.G. Catanoso, L. Boiardi, F. Cantini, C. Klersy, and G.G. Hunder.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Polymyalgia rheumatica (PMR) is a disease in which inflammation occurs throughout the body. Symptoms include weight loss; fever; muscle pain; aching of the neck, shoulder, and hip; and morning stiffness. The cause of PMR is unknown. It occurs most often in persons older than 50 years of age and increasingly often with advancing age. Polymyalgia rheumatica responds well to treatment with steroids, such as prednisone. However, patients usually need to stay on steroids for 1 to 2 years, and symptoms sometimes return (relapse) when steroid treatment is stopped. Patients can develop side effects from steroids, so we need better ways to treat PMR to decrease relapse and the amount of steroids needed to treat the disease. Infliximab is a drug that interacts with the immune system. A report suggested that infliximab decreased the amount of steroids needed in 4 patients with PMR who developed side effects from steroid treatment.

Why did the researchers do this particular study?

To find out whether treatment with infliximab improved outcomes for people with PMR.

Who was studied?

The researchers studied 51 patients with newly diagnosed PMR that were being treated with the steroid prednisone.

How was the study done?

The researchers assigned patients at random to receive an intravenous dose of either infliximab or a placebo (a substance that looked like infliximab but contained no active ingredient) at the start of the study and then after 2, 6, 14, and 22 weeks. All patients followed a schedule to slowly decrease the steroid dose from 15 mg to 0 mg over 16 weeks. If symptoms returned, they would need to increase the steroid dose and start to decrease the amount they received all over again. The researchers collected information on whether patients' symptoms returned (relapse) and on steroid dose over the course of the study.

What did the researchers find?

Infliximab did not seem to offer a large benefit in terms of preventing relapse of symptoms or in reducing the amount of steroids required for treatment of PMR.

What were the limitations of the study?

The study was small and lasted only 22 weeks, so the researchers could not rule out a small benefit of infliximab or a benefit if used for a longer period. Also, the study was too small to provide good information on the side effects of infliximab.

What are the implications of the study?

Infliximab is unlikely to result in large benefits when added to prednisone for patients with newly diagnosed PMR.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Adding Infliximab to the Treatment Regimen for Polymyalgia Rheumatica. Ann Intern Med. 2007;146:I–20. doi: https://doi.org/10.7326/0003-4819-146-9-200705010-00002

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2007;146(9):I-20.

DOI: 10.7326/0003-4819-146-9-200705010-00002

©
2007 American College of Physicians
0 Citations

See Also

Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica: A Randomized Trial
View MoreView Less

Related Articles

Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica: A Randomized Trial
Annals of Internal Medicine; 146 (9): 631-639
Annals for Educators - 2 May 2017
Annals of Internal Medicine; 166 (9): ED9
Patients with polymyalgia rheumatica had a 2.6-fold increased risk for vascular events at a median 7.8 y
Annals of Internal Medicine; 162 (2): JC12
Review: Azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn disease
Annals of Internal Medicine; 148 (12): JC4-9
View MoreView Less

Journal Club

Patients with polymyalgia rheumatica had a 2.6-fold increased risk for vascular events at a median 7.8 y
Annals of Internal Medicine; 162 (2): JC12
Review: Azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn disease
Annals of Internal Medicine; 148 (12): JC4-9
View MoreView Less

Related Point of Care

Polymyalgia Rheumatica
Annals of Internal Medicine; 166 (9): ITC65-ITC80
View MoreView Less

Related Topics

Giant Cell Arteritis/Polymyalgia Rheumatica
Rheumatology

Giant Cell Arteritis/Polymyalgia Rheumatica, Rheumatology.

PubMed Articles

[POSITION PAPER: ANTI-TNFα DRUG AND ANTI-DRUG MONITORING IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE].
Harefuah 2019;158(11):752-754.
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents.
BioDrugs 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×